No­vo fur­ther boosts ev­i­dence for semaglu­tide’s heart ben­e­fits be­yond weight loss: #ACC24

No­vo Nordisk’s semaglu­tide has hit a pair of pri­ma­ry end­points in a late-stage test in pa­tients with a trio of car­diometa­bol­ic con­di­tions, bol­ster­ing the com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER